Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer.
Journal: Cancer immunology research
Published: September 12, 2019
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 08, 2019
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 19, 2018
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 14, 2015
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 08, 2011
Showing 1-5 of 5
Last Updated: 09/26/2026